Data as of Mar 14
| +0.0013 / +1.62%|
Advanced Cell Technology, Inc. is a biotechnology company that is focused on developing and commercializing human embryonic and adult stem cell technology in the emerging fields of regenerative medicine. The company has three cellular product platforms based on stem cell technology. It is focused on commercializing its human embryonic stem cell (hESC)-based Retinal Pigment Epithelial (RPE) therapy for degenerative retinal disease. The company is also developing its hESC-based Hemangioblast (HG) platform for the treatment of blood and cardiovascular diseases. Additionally it is developing a method for scaled manufacturing of Mesenchymal Stem Cells (MSCs) from renewable pluripotent stem cell sources. The company is also developing therapeutic platforms using Corneal Endothelial Cells for use in treating corneal blindness, as well as retinal neural progenitor cells for use in treating glaucoma. Advanced Cell Technology was founded on May 18, 2000 and is headquartered in Marlborough, MA.
|Edward H. Myles||President, CFO & EVP-Corporate Development|
|Rita Parker||Operations Director|
|Eddy Anglade||Executive Vice President-Clinical Development|
|Robert P. Lanza||Chief Scientific Officer|
|Shi-Jiang Lu||Senior Director-Research|